GlassScriptPhysician profile
Eunsung Kim
NPI 1306371695
$4,846.75
in general payments reported to CMS, 2019-2025
23 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 94% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.61 · 2022: $679 · 2023: $993 · 2024: $1,377 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,111 · Education: $13.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,110.62 |
| Education | $13.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,506.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $613.68 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $469.70 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $406.82 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $312.80 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $198.71 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $164.73 | 2024-2025 | Rexulti |
| Eisai INC. | $163.99 | 2025 | |
| Pfizer INC. | $151.05 | 2021-2024 | |
| Abbvie INC. | $143.51 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.67 | 2022-2025 | Jardiance |
| Amgen INC. | $122.64 | 2023-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $96.56 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Viiv Healthcare Company | $80.33 | 2025 | Apretude |
| Sanofi Pasteur INC. | $64.87 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $63.07 | 2024 | Onzetra Xsail, Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $41.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.22 | 2024 | Hyqvia |
| Idorsia Pharmaceuticals US INC | $26.96 | 2022-2023 | Quviviq |
| Dynavax Technologies Corporation | $23.95 | 2025 | Heplisav-B |
| Medtronic, INC. | $22.45 | 2022 | |
| Vivus LLC | $14.19 | 2024 | Qsymia |
| Theracosbio, LLC | $4.98 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunsung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.